| PCMA Comments on Part D 2020 NPRM – December 21, 2018.pdf | |
| PCMA comments on Medicare and Medicaid Programs - Regulation To Require Drug Pricing Transparency - December 6, 2018.pdf | |
| PCMA Comments on ANPRM - International Pricing Index Model for Part B Drugs - December 6, 2018.pdf | |
| Final PCMA Comments on Section 1332 Waiver Guidance - November 27, 2018.pdf | |
| PCMA Comment to FDA on Citizen Petition Reforms FINAL 12-03-18.pdf | |
| PCMA Comments on Public Charge NPRM - November 28, 2018.pdf | |
| PCMA Comments on the Changes to the Medicare Claims and Medicare Prescription Drug Coverage Determination Appeals Procedures - November 28, 2018.pdf | |
| PCMA Comments on HHS OIG RFI on AKS Safe Harbors - October 23, 2018.pdf | |
| PCMA Comments on CAP RFI - September 21, 2018.pdf | |
| PCMA comments on proposed Medicare DIR Reporting Requirements for 2017 - May 4, 2018.pdf | |
| PCMA Comments on Short-Term Limited Duration Insurance NPRM - April 23, 2018.pdf | |
| PCMA Comments on Protecting Statutory Conscience Rights in Health Care NPRM - March 27 2018.pdf | |
| PCMA Comments on Advance Notice and 2019 Call Letter - March 2, 2018.pdf | |
| PCMA Comments on ASPE RFI - January 25, 2018.pdf | |
| PCMA comments on the 2019 Part D NPRM and RFI - January 16, 2018.pdf | |
